Pure Financial Statements From 2010 to 2026
| PURE Stock | USD 0.04 0.01 20.00% |
Check Pure Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pure Bioscience's main balance sheet or income statement drivers, such as , as well as many indicators such as . Pure financial statements analysis is a perfect complement when working with Pure Bioscience Valuation or Volatility modules.
Pure |
Pure Bioscience OTC Stock Return On Equity Analysis
Pure Bioscience's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Pure Bioscience Return On Equity | -1.29 |
Most of Pure Bioscience's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pure Bioscience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Pure Bioscience has a Return On Equity of -1.2879. This is 148.78% lower than that of the Household Products sector and 108.77% lower than that of the Consumer Staples industry. The return on equity for all United States stocks is notably higher than that of the company.
Pure Bioscience Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pure Bioscience's current stock value. Our valuation model uses many indicators to compare Pure Bioscience value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pure Bioscience competition to find correlations between indicators driving Pure Bioscience's intrinsic value. More Info.Pure Bioscience is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pure Bioscience's earnings, one of the primary drivers of an investment's value.About Pure Bioscience Financial Statements
Pure Bioscience stakeholders use historical fundamental indicators, such as Pure Bioscience's revenue or net income, to determine how well the company is positioned to perform in the future. Although Pure Bioscience investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pure Bioscience's assets and liabilities are reflected in the revenues and expenses on Pure Bioscience's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pure Bioscience. Please read more on our technical analysis and fundamental analysis pages.
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California. PURE BIOSCIENCE operates under Household Personal Products classification in the United States and is traded on OTC Exchange. It employs 10 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Other Information on Investing in Pure OTC Stock
Pure Bioscience financial ratios help investors to determine whether Pure OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pure with respect to the benefits of owning Pure Bioscience security.